We are live on
!
Find out more
EAM
Eventide Asset Management Portfolio holdings
AUM
$6.05B
1-Year Est. Return
76.64%
This Fund
S&P 500
This Quarter
Est. Return
+15.71%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$5.92B
AUM Growth
+$466M
(+8.6%)
Cap. Flow
-$28.9M
Cap. Flow
% of AUM
-0.49%
Top 10 Holdings %
Top 10 Hldgs %
26.27%
Holding
163
New
16
Increased
58
Reduced
30
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zentalis Pharmaceuticals
ZNTL
|
+$87.6M |
| 2 |
Guardant Health
GH
|
+$61.3M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
+$37.2M |
| 4 |
Toast
TOST
|
+$32M |
| 5 |
Lithia Motors
LAD
|
+$28.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$71.9M |
| 2 |
Doximity
DOCS
|
+$45M |
| 3 |
Enphase Energy
ENPH
|
+$36M |
| 4 |
Roper Technologies
ROP
|
+$31.6M |
| 5 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$31.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.76% |
| 2 | Technology | 22.95% |
| 3 | Industrials | 13.17% |
| 4 | Consumer Discretionary | 7.97% |
| 5 | Utilities | 3.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
EastGroup Properties
EGP
$11.3B
| $5.77M | 0.1% |
33,255
| – | – |
|
127
Transmedics
TMDX
$2.63B
| $5.67M | 0.1% |
+67,461
| New | +$5.16M |
|
128
Arcus Biosciences
RCUS
$3.55B
| $4.87M | 0.08% |
240,000
| – | – |
|
129
Ionis Pharmaceuticals
IONS
$8.81B
| $4.51M | 0.08% |
110,000
| – | – |
|
130
Arteris
AIP
$1.35B
| $2.72M | 0.05% |
398,774
-124,031
| -24% | -$670K |
|
131
NerdWallet
NRDS
$592M
| $1.41M | 0.02% |
+150,000
| New | +$1.69M |
|
132
NVIDIA
NVDA
$4.72T
| $520K | 0.01% |
12,290
+8,660
| +239% | +$288K |
|
133
ServiceNow
NOW
$114B
| $509K | 0.01% |
4,530
+940
| +26% | +$94K |
|
134
Edwards Lifesciences
EW
$50B
| $482K | 0.01% |
5,108
+1,078
| +27% | +$93.7K |
|
135
Compass
COMP
$8.56B
| $451K | 0.01% |
+128,879
| New | +$423K |
|
136
Align Technology
ALGN
$12.4B
| $417K | 0.01% |
+1,178
| New | +$375K |
|
137
TSMC
TSM
$2.09T
| $367K | 0.01% |
3,640
+1,613
| +80% | +$150K |
|
138
NextEra Energy
NEE
$183B
| $235K | ﹤0.01% |
3,163
-431
| -12% | -$32.6K |
|
139
ADC Therapeutics
ADCT
$141M
| – | – |
-1,675,959
| Closed | -$3.27M |
|
140
ALX Oncology
ALXO
$262M
| – | – |
-664,829
| Closed | -$3.01M |
|
141
Annexon
ANNX
$863M
| – | – |
-1,867,250
| Closed | -$7.19M |
|
142
BILL Holdings
BILL
$4.52B
| – | – |
-264,398
| Closed | -$21.5M |
|
143
Crown Castle
CCI
$33.4B
| – | – |
-235,052
| Closed | -$31.5M |
|
144
CALL
dLocal
DLO
$4.41B
| – | – |
-3,900
| Closed | -$70 |
|
|
145
Enphase Energy
ENPH
$4.94B
| – | – |
-171,081
| Closed | -$36M |
|
|
KYNB
146
Kyntra Bio
KYNB
$27.5M
| – | – |
-38,400
| Closed | -$17.9M |
|
147
Generac Holdings
GNRC
$11.3B
| – | – |
-103
| Closed | -$11.1K |
|
148
Immunovant
IMVT
$8.11B
| – | – |
-1,390,000
| Closed | -$21.6M |
|
149
MongoDB
MDB
$26.2B
| – | – |
-81
| Closed | -$18.9K |
|
150
PTC Therapeutics
PTCT
$6.26B
| – | – |
-34,047
| Closed | -$1.65M |
|
Similar funds
HPG
EMPI
RCG
JWBC
AAM
AA
CM
CIS
Eventide Asset Management's Q2 2023 Portfolio in Review
As of Q2 2023, Eventide Asset Management held 163 positions worth $5.92B, up 8.6% from $5.45B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Eventide Asset Management's Q2 2023 filing shows 16 new, 58 increased, 30 reduced and 24 closed positions. Its largest new stake was Toast: 1,603,866 shares worth $36.2M. The largest sale was Prometheus Biosciences, Inc. Common Stock, an estimated $71.9M.
By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 43% a quarter earlier, followed by Technology and Industrials.
- Eventide Asset Management's largest Q2 2023 buy was Toast: 1,603,866 shares worth $36.2M.
- Eventide Asset Management added most to Zentalis Pharmaceuticals in Q2 2023, an estimated $87.6M increase.
- Eventide Asset Management's biggest Q2 2023 reduction was Doximity, cutting an estimated $45M.
- Eventide Asset Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $71.9M.
- Eventide Asset Management's ten largest holdings make up 26% of its $5.92B portfolio in Q2 2023.
- Eventide Asset Management opened 16 new positions and closed 24 in Q2 2023.
- Eventide Asset Management's portfolio value rose 8.6% quarter-over-quarter to $5.92B.
Based on Eventide Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.